According to the KEYNOTE-024 phase 3 randomized trial, first-line pembrolizumab monotherapy showed better efficacy and safety than platinum-based chemotherapy in patients with advanced NSCLC and PDL1 TPS ≥50% (14). Here, CD274 is linked to non-small cell lung carcinoma.